The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so that physicians would prescribe a specific migraine drug to patients.
Pfizer agreed to pay nearly $60 million to resolve allegations that its Biohaven Pharmaceuticals unit paid kickbacks to entice physicians to prescribe a migraine treatment. The alleged violations ...
Pharma giant Pfizer has agreed to pay $59 million to settle a federal lawsuit accusing a local biopharmaceutical company of ...
The kickbacks were meant to encourage doctors to prescribe the migraine drug Nurtec ODT ... Pfizer completed the acquisition of Biohaven Pharmaceutical Holding Co., the maker of Nurtec ODT ...
Hosted on MSN25d
Pfizer settles Biohaven kickback case with DOJ for $60MPfizer (NYSE:PFE) has agreed to pay nearly $60M to resolve allegations that its Biohaven unit paid kickbacks to physicians to induce prescriptions for its migraine drug Nurtec ODT. The U.S ...
Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks so doctors would prescribe the migraine drug Nurtec ODT ...
Biohaven previously received both Fast-Track and Orphan Drug Designation (ODD ... TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders ...
Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...
Biohaven (BHVN) announced that the FDA has accepted for review the company’s New Drug Application, or NDA, for troriluzole for the treatment of ...
Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks so doctors would prescribe the migraine drug Nurtec ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback